News

Fierce Biotech38m

Scancell picks winner from phase 2 cancer vaccine face off, choosing next-gen prospect for pivotal trial

Scancell has linked iSCIB1+ to a 69% response rate in advanced melanoma, lead | Scancell has linked iSCIB1+ to a 69% response ...
Healio19m

Oral danegaptide for diabetic retinopathy successfully completes phase 1b trial

Danegaptide, a potential oral therapy for nonproliferative diabetic retinopathy, is advancing to a phase 2 trial after ...